PA
Therapeutic Areas
Autolus Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Obecabtagene autoleucel (obe-cel) | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 / Pivotal |
| AUTO1/22 | Relapsed/Refractory Pediatric B-ALL | Phase 1 |
| AUTO6NG | Advanced Neuroblastoma | Phase 1 |
| AUTO8 | Relapsed/Refractory Multiple Myeloma | Phase 1 |
| AUTO4 | Relapsed/Refractory TRBC1+ T-cell Lymphoma | Phase 1 |
Leadership Team at Autolus Therapeutics
DC
Dr. Christian Itin, Ph.D.
Chairman and Chief Executive Officer
DM
Dr. Martin Pule, M.D., Ph.D.
Chief Scientific Officer, Founder
DS
Dr. Simon Cartwright, Ph.D.
Chief Development Officer
DW
Dr. William (Billy) Savage, M.D., Ph.D.
Chief Medical Officer
AO
Andrew Oakley, B.Sc., FCA
Chief Financial Officer